Geneoscopy has secured $105 million in funding, led by Bio-Rad Laboratories, to advance its groundbreaking gastrointestinal diagnostics, including the launch of its non-invasive colorectal cancer screening test, ColoSense. This capital also enables the development of innovative diagnostic solutions for inflammatory bowel disease, addressing significant unmet needs.
The funding will accelerate the commercial rollout of ColoSense, an at-home, stool-based test, and enhance accessibility through a collaboration with Labcorp. ColoSense leverages Geneoscopy’s RNA isolation technology and Bio-Rad’s Droplet Digital PCR (ddPCR) platform for highly accurate cancer detection.
Norman Schwartz, Bio-Rad’s CEO, highlighted the technology’s potential, saying, “This investment underscores our commitment to advancing science and improving healthcare outcomes.” Geneoscopy’s CEO, Andrew Barnell, added that the financing will prioritise patient well-being and reshape gastrointestinal health diagnostics.
Read the full story here.
